Market Research · Healthcare
Size a healthcare market with the payer and adoption reality built in.
We size the addressable market, map the competitive and reimbursement landscape, and surface the adoption barriers that make or break uptake. This is market research—not regulatory, clinical, or reimbursement advice.
The Outcome
What market research actually gives you
Not a slide deck of generic stats — a defensible read of your market and a decision you can act on.
A sizing model grounded in real denominators
Addressable population built from procedure volumes, prevalence, or facility counts—sourced and triangulated, not assumed.
The reimbursement and payer picture
How the space is paid for today—coverage context, coding pathways, and payer mix—as market intelligence, not billing guidance.
A clear-eyed read on adoption
The clinical, economic, and workflow barriers that slow uptake, mapped so your plan accounts for them.
How we work
Here’s how we’d research it — sourced, not borrowed
We won’t hand you a report full of borrowed numbers. What follows is exactly how we’d research your market and what you’d get — every figure sourced, triangulated, and built bottom-up rather than pulled from a headline. Where the data is thin, we say so and present ranges with the derivation shown, so the work stands up to a board, a lender, or an investor.
Who it’s for: Medtech founders, health-services operators, and investors evaluating a device, diagnostic, or care model—who need a market read that respects how healthcare actually buys, pays, and adopts.
The Core Questions
Four research workstreams
Each engagement runs as focused workstreams built around the decisions you face. Here is the strategic question each one answers and how we’d go about answering it. Throughout, we work as market researchers—we do not provide regulatory, clinical, or reimbursement advice.
01
Market sizing
The question: How large is the addressable market once you count real patients, procedures, or sites?
What we’d deliver: A bottom-up model built on epidemiological denominators—prevalence, incidence, procedure volumes, or facility counts from public health datasets and registries—narrowed by eligibility and setting, then priced. We triangulate against published estimates, show ranges where data is thin, and cite every source.
02
Reimbursement & payer context
The question: How is this space paid for, and does the money flow support your model?
What we’d deliver: A market-intelligence view of the payment environment: relevant coding pathways, coverage posture, and payer mix, assembled from public fee schedules, coverage policies, and published literature. We frame how reimbursement shapes demand and pricing—explicitly as research, not billing or coverage advice.
03
Competitive landscape
The question: Who else serves this clinical need, and how are they positioned?
What we’d deliver: A structured map of incumbents, emerging entrants, and standard-of-care alternatives across clinical positioning, target setting, evidence base, and go-to-market. Built from company disclosures, clinical-trial registries, published studies, and product labeling, then charted for clustering and gaps.
04
Adoption barriers & entry context
The question: What stands between a sound product and actual uptake?
What we’d deliver: We identify the friction points—clinician workflow, economic buyer incentives, evidence expectations, and purchasing pathways—and assess how each affects a realistic entry plan. Output is a regulatory-aware entry brief that flags where specialist regulatory or clinical counsel is needed, without substituting for it.
The Fuller Scope
The fuller scope
Beyond the four core workstreams, engagements often extend into the questions below. We scope only what the decision needs, and we stay in the research lane.
Care-setting segmentation
Demand split across hospital, ambulatory, and home settings, since the same product faces very different economics in each.
Buyer & stakeholder mapping
Who decides—clinician, procurement, administrator, payer—and what each cares about, so the plan speaks to the real decision chain.
Evidence-landscape review
What clinical and economic evidence competitors have published, and what the field expects, as market context for your positioning.
Adjacent-indication sizing
The size and competitive picture of neighboring indications or use cases you might expand into.
Pricing environment
How comparable products and procedures are priced and reimbursed, framing the viable range—not a price recommendation.
Demand & prevalence deep-dives
Rigorous epidemiological work where the patient denominator is the crux of the sizing question.
Go/no-go framing
A structured brief consolidating sizing, reimbursement, competition, and adoption into a decision, with the thresholds that would change it.
Decisions This Research Informs
Decisions this research informs
Research is only worth it if it changes a decision. Here’s what ours is built to inform.
How many patients or procedures are truly addressable?
Bottom-up sizing on epidemiological denominators, narrowed by eligibility and setting.
Does the reimbursement environment support demand?
Market-intelligence read of coding, coverage, and payer mix (research, not advice).
Which care setting do we target first?
Setting-level sizing and economics across hospital, ambulatory, and home.
How crowded is the clinical space?
Competitive and evidence-landscape mapping across alternatives and standard of care.
What will slow adoption?
Structured barrier analysis across workflow, economics, and evidence expectations.
Should we pursue this market?
Go/no-go brief integrating sizing, payment, competition, and adoption reality.
To size a device market, we start from a real denominator—say, annual US procedure volume for a given indication drawn from public registries or claims-based literature—narrow it by clinical eligibility and target care setting, then apply a modeled price to reach an addressable figure, triangulated against any published market estimate with the gap explained. Reimbursement context is presented as market intelligence: how comparable products are coded and covered today, sourced from public fee schedules and coverage policies, never as billing or coverage guidance. Every figure ties to a named source or stated assumption, ranges are shown where data is uncertain, and we do not invent prevalence rates, market values, or growth rates.
The Engagement
Rigorous, sourced, and decision-ready
A scoped research engagement built to answer specific questions — not a generic market overview. We frame the questions, run the desk and primary research, size the opportunity bottom-up, and deliver a synthesis you can put in front of a board or an investor.
Every number is defensible. We show the sources, the method, and the range — so the read holds up to scrutiny instead of collapsing on the first hard question.
Every market is different. The scope is where we frame the questions worth answering.
How It Works
From question to decision-ready answer
-
Scope & questions
We define the decision at stake and the specific questions the research must answer — so nothing gets sized or studied that doesn’t move the call.
-
Desk & primary research
Triangulated secondary sources plus primary inputs where they matter — competitor teardowns, customer signals, channel and pricing reads.
-
Bottom-up sizing & analysis
A TAM/SAM/SOM built from documented inputs, a competitive map, and the whitespace — with every figure traceable to a source.
-
Synthesis & recommendation
The findings resolved into a clear position and a go/no-go, written to stand up to a board, a lender, or an investor.
-
Decision support
We stay on to pressure-test the call, brief stakeholders, and feed the research into the launch, raise, or entry plan it informs.
FAQ
Healthcare & Medical Devices — market-research questions
Do you provide regulatory or clinical advice?
No. We do market research. We can flag where a regulatory pathway or clinical-evidence question is material to the market, and where you’ll need specialist regulatory, clinical, or legal counsel—but we don’t substitute for it.
Is your reimbursement work billing or coverage advice?
No. We describe the payment environment as market intelligence—how the space is coded, covered, and paid for today—so you can judge demand and pricing. Coding and coverage decisions require qualified reimbursement counsel.
Where do your patient and procedure numbers come from?
Public health datasets, disease registries, claims-based literature, and peer-reviewed studies. We cite each source and show a range when the underlying data is uncertain.
Can you size a market for a product still in development?
Yes, on an addressable-population basis with the eligibility and adoption assumptions made explicit. We’ll be clear about what’s modeled versus observed.
Do you run clinician or patient interviews?
When the decision needs primary signal on workflow, willingness, or unmet need, we design and run structured interviews—as market research, distinct from clinical investigation.
How do you handle adoption barriers?
We map the friction across the real decision chain—clinician workflow, economic buyer, evidence expectations, purchasing pathway—and assess how each affects realistic uptake.
Will this support a fundraise or board decision?
It’s a common use. Because the denominators are sourced and assumptions visible, the sizing holds up under diligence.
Do you recommend our pricing or regulatory strategy?
We supply the competitive, payment, and demand evidence and lay out trade-offs. Pricing, regulatory, and clinical strategy remain yours, made with the appropriate specialist advisors.
The Full Practice